Skip to content
Logo
  • Home
  • FeNO
    • What is FeNO?
    • FeNO in asthma
    • Benefits of FeNO use
    • Measuring FeNO with the NObreath®
  • NObreath®
    • What is the NObreath®?
    • Already own a NObreath®
    • How to use the NObreath®
    • Consumables
    • Where to buy?
    • Literature
  • Forum
  • News
  • Medical Advisory Board
  • Software
  • Support
    • Educational Portal
    • FAQs
    • Literature
    • How to videos
    • Coronavirus and FeNO testing
  • Contact
  • United States
    • English
    • United States
Sep 08
NObreath FeNO monitor in use

Intermedical UK exhibits the new and improved NObreath at ARTP 2019

Bedfont’s long-standing UK distributor, Intermedical UK, will be exhibiting their breath analysis medical products at the annual ARTP conference.

Intermedical UK, a bistributor for nearly 10 years, will be exhibiting the 2nd generation NObreath at the annual Association for Respiratory Technology & Physiology (ARTP) conference and can be found at Stand 25.

The NObreath® offers a quick, simple and non-invasive method of measuring FeNO to assess airway inflammation.It aids in the diagnosis and management of asthma.

Interpreting FeNO levels aids in identifying patients who do/do not require on-going treatment1 whilst also differentiating between allergic (eosinophilic) and non-allergic asthma2, and if used daily, FeNO measurements can help to predict exacerbations and attacks3.

New Features

The 2nd generation NObreath® has a fresh and aesthetically pleasing design with a full-colour touchscreen. New features of the also include the ability to save patient profiles on the device, Bluetooth connectivity, and SteriTouch® technology for optimum infection control. Furthermore, the NObreath® comes with free patient management software allowing the equipment to synchronise with a PC. This enables reports to be generated, data to be backed up, and much more.

The Acting Managing Director at Intermedical, Livio Gagliardi, said – “We’re excited to bring the NObreath® to ARTP this year. It’s a great opportunity to talk about the benefits of measuring FeNO when monitoring asthma and airway inflammation – especially now it is recommended in the NICE guidance. We believe that the new NObreath® will make FeNO monitoring quicker and easier for healthcare professionals and patients alike.”

This year, ARTP is taking place between 31 January and 1st February in Glasgow.

 

REFERENCES

  1. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
  2. Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
  3. Harkins M. Exhaled Nitric Oxide Predicts Asthma Exacerbation [Internet]. Taylor & Francis. 2017 [cited 21 September 2017]. Available from: http://www.tandfonline.com/doi/abs/10.1081/JAS-120033990

Leave a reply Cancel reply

Your email address will not be published. Required fields are marked *

Contact Details

Bedfont® Scientific Ltd
Station Road, Harrietsham, Maidstone
Kent, ME17 1JA, England

Tel: +44(0)1622 851122
Email: ask@bedfont.com

Products

NObreath®

Smokerlyzer®

Gastrolyzer®

ToxCO®

Medi-Gas Check

Accreditations

ISO 13485:2016

Bedfont EC REP - Emergo

Useful Links

What is FeNO?

FeNOchart™

What is the NObreath®?

Resources

FAQs

Contact Us


References



White Bedfont text logo

© 1976-2025 Bedfont® Scientific Ltd., all rights reserved | Incorporated in England and Wales under registered number: 1289798

Legal Stuff | Privacy Notice | Help Centre